Ignite Biomedical
Ignite Biomedical is a private precision medicine company that develops blood-based mRNA biomarker diagnostics, treatment response predictors, and novel drug targets across autoimmune disease, ASD, PTSD, and SUD, using the Emerge quantitative AI platform licensed from Liquid Biosciences.
- Company typePrivate
- Founded2022
- HeadquartersFramingham, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Ignite Biomedical does
Ignite Biomedical is a privately held precision medicine company founded in November 2022 by pharmacists Claudio Faria (CEO) and Jake Nichols (CMO), headquartered in Framingham, Massachusetts with 1–10 employees. The company develops algorithmic mRNA biomarkers for blood-based diagnostics, treatment response predictors (TRPs), and novel drug targets across four therapeutic areas: inflammatory bowel disease (IBD) and autoimmune disease, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), and substance use disorder (SUD). Its diagnostic pipeline (IGNB-001 through IGNB-006) includes a validated TNFi Treatment Response Predictor for IBD, rheumatoid arthritis, and psoriasis, plus diagnostics and prognostic tests for IBD, ASD, SUD, and PTSD; a therapeutic pipeline (IGNB-101 through IGNB-103) targets first-in-class drug development in ASD, SUD, and PTSD, where no FDA-approved disease-modifying drugs currently exist for ASD.
The company's underlying technology is the Emerge quantitative AI platform from Liquid Biosciences, which uses evolutionary computing to model causal biology directly from patient data and is claimed to have completed 300+ analytic programs across 53 diseases with a 100% prospective validation success rate. Discovery outputs are translated into blood-based TaqMan assays developed and manufactured via Calbiotech (CDMO) and analytically validated at Morningstar Laboratories (CLIA-certified, CAP-accredited), with reagent supply through ThermoFisher Scientific. Ignite plans to commercialize diagnostics through CLIA-certified laboratories and pursue licensing or co-development arrangements for its drug-target pipeline with global biopharma partners; pricing, payer coverage, and commercial revenue are not yet disclosed.
The business model is structured around two future revenue streams: per-test clinical laboratory revenue from blood-based diagnostics and TRPs ordered by physicians (targeting healthcare providers, payers, and health systems), and licensing/royalty income from novel drug targets and companion-diagnostic co-development with pharmaceutical and biotechnology partners. As of the latest disclosed data, the company remains pre-revenue, has raised only $174,282 in a single funding round (July 2025), and is dependent on the continued availability of the Liquid Biosciences Emerge platform as its sole discovery engine. Strategic governance ties include board representation from Liquid Biosciences, IPSEN, and GenMAV.
Ignite Biomedical firmographics
Firmographics- Name
- Ignite Biomedical
- Legal name
- Ignite Biomedical
- Website
- https://ignitebiomedical.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ignite Biomedical is a private precision medicine company that develops blood-based mRNA biomarker diagnostics, treatment response predictors, and novel drug targets across autoimmune disease, ASD, PTSD, and SUD, using the Emerge quantitative AI platform licensed from Liquid Biosciences.
- Ownership category
- akta.pro rank
Ignite Biomedical industry classification
Industry- Product category
- Precision Diagnostics and Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)
Keywords
Where Ignite Biomedical is headquartered
LocationHeadquarters
- HQ city
- Framingham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ignite Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- Diagnostic Biomarker Tests: Revenue from blood-based mRNA diagnostic tests sold to healthcare systems, hospitals, and clinicians. Tests provide rapid, objective disease diagnosis for conditions including ASD, SUD, PTSD, and IBD. Revenue generated through laboratory testing services and potentially reagent/test kit sales.
- Treatment Response Predictor (TRP) Tests: Revenue from predictive diagnostic tests that identify patient responders and non-responders to specific drug therapies. The TNFi TRP predicts response to TNF-alpha inhibitors, enabling clinicians to make individualized treatment decisions. Helps reduce wasteful spending on ineffective treatments.
- Precision Therapeutics: Revenue from novel drug targets and therapeutics developed targeting root causes of disease in ASD, SUD, PTSD, and other neuropsychiatric/autoimmune conditions. No FDA-approved drugs currently exist for direct treatment of ASD, representing significant unmet market opportunity. Potential licensing or co-development arrangements with pharmaceutical partners.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Ignite Biomedical product offering
Product offeringCore offering
Ignite Biomedical develops AI-driven blood-based mRNA diagnostic tests, treatment response predictors (TRPs), and precision therapeutic drug targets across autoimmune diseases, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), and substance use disorder (SUD). Products are discovered through the proprietary Emerge quantitative AI platform (via partnership with Liquid Biosciences), with the diagnostic pipeline (IGNB-001 through IGNB-006) intended for clinical laboratory use by physicians and the therapeutic pipeline (IGNB-101 through IGNB-103) representing novel drug targets for licensing or co-development with biopharma partners.
Product overview
Ignite Biomedical operates as an Rx/Dx company developing a unified portfolio of AI-driven precision diagnostics, treatment response predictors (TRPs), and precision therapeutics across four therapeutic areas: immunology, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), and substance use disorder (SUD). The diagnostic pipeline includes nine blood-based mRNA biomarker products (IGNB-001 through IGNB-006) covering IBD, rheumatoid arthritis, psoriasis, ASD, SUD, and PTSD. The therapeutic pipeline includes three precision drug targets (IGNB-101 through IGNB-103). All products are discovered using the Emerge quantitative AI platform (licensed from Liquid Biosciences) and leverage mRNA biomarkers. The diagnostic and TRP products form the near-term commercial pathway; therapeutic candidates (IGNB-101/102/103) represent the long-term drug development pipeline. Accuracy claims exceed 90–95% across the portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- TNFi Treatment Response Predictor (TRP) Blood test detecting mRNA biomarkers highly predictive of TNFi response and non-response across all FDA-approved indications including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and psoriatic arthritis. Enables clinicians to identify patients likely to benefit from tumor necrosis factor inhibitor therapy before prescribing.
- IBD TNFi TRP (IGNB-001A) Sub-indication variant of the TNFi TRP for patients with Crohn's disease and ulcerative colitis (inflammatory bowel disease).
- RA TNFi TRP (IGNB-001B) Sub-indication variant of the TNFi TRP for patients with rheumatoid arthritis.
- PSO/PSA TNFi TRP (IGNB-001C) Sub-indication variant of the TNFi TRP for patients with psoriasis and psoriatic arthritis.
- IBD Diagnostic and Prognostic (IGNB-002)
Quantifiable outcome
- Over 90% sensitivity and specificity for ASD biomarker detection
- +5 more outcomes
Companies that use Ignite Biomedical
Customer profileSegments4 records
Ideal customer profiles3 records
Ignite Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Ignite Biomedical partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Liquid BiosciencescoreIgnite Biomedical's primary technology partner utilizing the Emerge AI platform for biomarker and drug target discovery. Emerge is the only quantitative AI platform in biopharma using evolutionary computing to model causal biology directly from patient data. Partnership has yielded biomarker discoveries for ASD (November 2025), SUD (April 2025), and PTSD, plus molecular drug targets for all three neuropsychiatric conditions. Emerge has completed 300+ projects across 53 diseases with 100% prospective validation success rate. The collaboration was expanded in June 2026 for first-in-class drug target discovery.
- CalbiotechcoreU.S.-based Contract Development and Manufacturing Organization (CDMO) specializing in assay development and manufacturing for in vitro diagnostics. Headquartered in California with ISO 13485 certification at FDA-registered facility. Supports end-to-end development including feasibility studies, assay optimization, analytical validation, regulatory support, and commercial production. Currently supporting ASD diagnostic assay development and validation for Ignite.
- Morningstar Laboratories (MSL)coreCLIA-certified and CAP-accredited laboratory, subsidiary of Smart Health Diagnostics Company. Conducted analytical validation for Ignite's TNFi Treatment Response Predictor (TRP), confirming exceptional performance across precision, repeatability, linearity, sensitivity, stability, and robustness parameters. Validation utilized TaqMan Gene Expression Assays targeting eight biomarkers.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Ignite Biomedical competitors and assessment
Company assessmentBroad incumbents
- Myriad Genetics: Molecular diagnostics company with a broad portfolio including companion diagnostics and treatment response predictors across multiple therapeutic areas. Comparable to Ignite's TRP business model, particularly after acquiring Crescendo Bioscience (Vectra DA) which addresses autoimmune treatment response.
- Tempus Labs: AI-driven precision medicine platform combining multi-modal data, diagnostics, and therapeutics. Comparable to Ignite's data-driven biomarker and therapeutic approach across multiple disease areas, though at much larger scale.
- Foundation Medicine: Molecular diagnostics leader (Roche subsidiary) providing comprehensive genomic profiling for oncology treatment selection. Comparable as a blood-based molecular diagnostic company serving clinicians, though Ignite's focus is autoimmune and CNS rather than oncology.
- Guardant Health: Leading liquid biopsy and molecular diagnostics company with CLIA lab infrastructure and payor relationships. Comparable as a blood-based diagnostic commercialization model, though focused on oncology rather than autoimmune/neuropsych.
- Natera: Molecular diagnostics company specializing in cell-free DNA testing and treatment monitoring across oncology and reproductive health. Comparable as a blood-based diagnostic specialist with CLIA lab operations and payor relationships.
Emerging players
- SOPHiA Genetics: AI-powered genomics and molecular diagnostics company offering a cloud-based platform for clinical genomic analysis. Comparable in combining AI analytics with diagnostic applications across multiple disease areas.
- Lantern Pharma: AI-driven precision oncology drug development company using machine learning to identify patient populations and drug targets. Comparable to Ignite's quantitative AI approach for biomarker-driven therapeutic development, though focused exclusively on oncology.
Direct peers
- Insitro: AI-driven drug discovery and biomarker platform combining machine learning with biological data. Most directly comparable to Ignite's use of Liquid Biosciences' Emerge AI to discover biomarkers and drug targets across multiple therapeutic areas.
- Verge Genomics: AI-driven drug discovery company specifically focused on neurodegenerative and neurological diseases using patient-derived data. Highly comparable to Ignite's quantitative AI approach for CNS conditions (ASD, PTSD).
- Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-throughput biology with machine learning to identify novel therapeutic targets. Comparable to Ignite's AI-led biomarker and drug target discovery approach, though Recursion is more asset-focused and oncology/neuro-centric.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ignite Biomedical social profiles
Digital presenceIgnite Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ignite Biomedical leadership team
Management profileNumber of profiles
Profiles7 records
Ignite Biomedical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ignite Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ignite Biomedical
What does Ignite Biomedical do?
Ignite Biomedical develops AI-driven blood-based mRNA diagnostic tests, treatment response predictors (TRPs), and precision therapeutic drug targets across autoimmune diseases, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), and substance use disorder (SUD). Products are discovered through the proprietary Emerge quantitative AI platform (via partnership with Liquid Biosciences), with the diagnostic pipeline (IGNB-001 through IGNB-006) intended for clinical laboratory use by physicians and the therapeutic pipeline (IGNB-101 through IGNB-103) representing novel drug targets for licensing or co-development with biopharma partners.
Is Ignite Biomedical a public or private company?
Ignite Biomedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ignite Biomedical founded?
Ignite Biomedical was founded in 2022. It employs 1 to 10 people.
Where is Ignite Biomedical based?
Ignite Biomedical is headquartered in Framingham, United States, in the North America region.
How does Ignite Biomedical make money?
Three revenue lines are on record. Diagnostic Biomarker Tests are the primary driver. The others are treatment Response Predictor (TRP) Tests and precision Therapeutics.
Who are Ignite Biomedical's main competitors?
Broad incumbents on record are Myriad Genetics, Tempus Labs, Foundation Medicine, Guardant Health and Natera. Emerging players are SOPHiA Genetics and Lantern Pharma. Direct peers are Insitro, Verge Genomics and Recursion Pharmaceuticals.
Does Ignite Biomedical have an API?
No public API is recorded for Ignite Biomedical.
What industry is Ignite Biomedical in?
Ignite Biomedical's product category is Precision Diagnostics and Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2835.